Showing results (21-30 of 66) with videos related to

Sort By:
Pageof 7
Cancers|February 5, 2020
HDAC6-an Emerging Target Against Chronic Myeloid Leukemia?Hélène Losson, Michael Schnekenburger, Mario Dicato, et al.
Epigenomics|February 18, 2015
Histone deacetylase 6 in health and diseaseCarole Seidel, Michael Schnekenburger, Mario Dicato, et al.
Biochemical Pharmacology|January 28, 2012
DNA demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugsJessica Charlet, Michael Schnekenburger, Keith W Brown, et al.
Epigenomics|December 1, 2011
Epigenomics of leukemia: from mechanisms to therapeutic applicationsCristina Florean, Michael Schnekenburger, Cindy Grandjenette, et al.
Biochimie|May 26, 2012
Chromatin-modifying agents in anti-cancer therapyCarole Seidel, Cristina Florean, Michael Schnekenburger, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|February 13, 2014
The Ah receptor recruits IKKα to its target binding motifs to phosphorylate serine-10 in histone H3 required for transcriptional activationHisaka Kurita, Michael Schnekenburger, Jerald L Ovesen, et al.
Biochemical Pharmacology|April 2, 2011
Reversible epigenetic fingerprint-mediated glutathione-S-transferase P1 gene silencing in human leukemia cell linesTommy Karius, Michael Schnekenburger, Jenny Ghelfi, et al.
Biochemical Pharmacology|September 22, 2014
Valproic acid regulates erythro-megakaryocytic differentiation through the modulation of transcription factors and microRNA regulatory micro-networksAnne Trécul, Franck Morceau, Anthoula Gaigneaux, et al.
Cancer Letters|November 9, 2005
Tumor necrosis factor alpha inhibits aclacinomycin A-induced erythroid differentiation of K562 cells via GATA-1Franck Morceau, Michael Schnekenburger, Romain Blasius, et al.
Toxicology|February 20, 2008
Repression of Ah receptor and induction of transforming growth factor-beta genes in DEN-induced mouse liver tumorsLi Peng, Christopher N Mayhew, Michael Schnekenburger, et al.
Pageof 7